Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IRIS Phase-1

Financiado

Cerrado

A revolutionary blood test to easily diagnose and prevent deadly complications o...

A revolutionary blood test to easily diagnose and prevent deadly complications of organs and tissue transplants. Transplantations are life-saving treatments, often representing the only option for people with severe disease such as blood cancers. Unfortunately, complications linked to transplants are so high that they are current limiting th... ver más

30/11/2019

Marx Biotech.

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

MARX BIOTECHNOLOGY LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-11-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Marx Biotech.

50.00K€ | Lider

ESPINA OBRAS HIDRAULICAS

273.77K€ | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

EU-TRAIN The EUropean TRAnsplantation and INnovation EU TRAIN conso... 7M€ Cerrado

TRANSBIO A BIOmarker based assay for prognosis and monitoring in rena... 71K€ Cerrado

ECP TOLERANCE An Investigation into Tolerance Induction by Extracorporeal... 45K€ Cerrado

DESARROLLO Y VALIDACIÓN DE UN SISTEMA INTELIG... DESARROLLO Y VALIDACIÓN DE UN SISTEMA INTELIGENTE NO INVASIV... 292K€ Cerrado

uPROPHET uPROPHET Urinary PROteomics in Predicting HEart Transplanta... 148K€ Cerrado

GvHDCure Understanding the dynamics of the immune system to cure graf... 2M€ Cerrado

Duración del proyecto: 4 meses Fecha Inicio: 2019-07-26
Fecha Fin: 2019-11-30

Líder del proyecto

MARX BIOTECHNOLOGY LTD No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Transplantations are life-saving treatments, often representing the only option for people with severe disease such as blood cancers. Unfortunately, complications linked to transplants are so high that they are current limiting the increase of adoption of transplantations. Specifically, Graft versus Host Disease occurs in up to 80% cases after receiving bone marrow from a donour and poses a serious threat to the life of patients already in critical condition. Graft versus Host Disease, today, can only be suspected when it is already at an advanced state, i.e. when clinical symptoms appear. However, symptoms are not unique, thus invasive biopsies are needed for a certain diagnosis. At this stage, even more time has been wasted before starting an effective drug treatment: the mortality risk can reach 95%, the hospitalization period lasts months instead than weeks and so drug treatments, that have to be stronger and more aggressive. MarxBio for the first time in the world was able to link a particular enzyme called GSK-3beta to the onset of Graft versus Host Disease and, specifically, to the proliferation of donor’s T-cells that attack the host. The Company has the unique knowhow to monitor the complex pathways of GSK-3beta to diagnose and monitor the progression of the disease, through the use of tens of different, specific antibodies. All of this know-how has been enclosed in a disposable protein chip, so a simple blood test, instead of a biopsy, is required to detect the disease: results can be obtained in every laboratory, with the use of a standard fluorescence scanner. Scientific results have been published and intellectual property has been protected with a patent portfolio. During Phase 1 project the Company will assess the scale-up plan and the clinical trials to be conducted to validate the diagnostic kit, and will establish a sound go-to-market strategy to ensure a swift market uptake of the proposed solution.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores